000168329 001__ 168329 000168329 005__ 20260204153543.0 000168329 0247_ $$2doi$$a10.1111/pace.14183 000168329 0248_ $$2sideral$$a146835 000168329 037__ $$aART-2021-146835 000168329 041__ $$aeng 000168329 100__ $$aBerruezo A 000168329 245__ $$aThe role of imaging in catheter ablation of ventricular arrhythmias. 000168329 260__ $$c2021 000168329 5060_ $$aAccess copy available to the general public$$fUnrestricted 000168329 5203_ $$aLate gadolinium enhancement cardiac magnetic resonance (LGE-CMR) and multidetector cardiac computed tomography (MDCT) have emerged as novel, fascinating imaging tools for arrhythmogenic substrate identification and characterization. The role of these techniques for aiding and guiding the catheter ablation of ventricular tachycardia, either as a complement or a surrogate of the electroanatomic map, has been rising in recent years. Integrating pixel signal intensity maps or wall thickness maps delivered from LGE-CMR or MDCT, respectively, into the navigation system has become a cornerstone for VT ablation procedures in a few centers of excellence around the world. The pre-procedure scar characterization offers some advantages, helping decide for the best procedure planning and approach; complete substrate identification and characterization, helping to focus electroanatomical mapping in regions of interest and also has a positive impact in procedure efficiency and outcomes. In the present article, we perform a review of the most practical aspects for using LGE-CMR or MDCT when a VT ablation procedure is planned, from the image acquisition to the integration into the navigation system, analyzing the current role of the LGE-CMR and MDCT for arrhythmogenic substrate characterization as well as for guiding VT ablation. 000168329 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000168329 590__ $$a1.912$$b2021 000168329 591__ $$aENGINEERING, BIOMEDICAL$$b78 / 98 = 0.796$$c2021$$dQ4$$eT3 000168329 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b113 / 143 = 0.79$$c2021$$dQ4$$eT3 000168329 592__ $$a0.589$$b2021 000168329 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2 000168329 593__ $$aCardiology and Cardiovascular Medicine$$c2021$$dQ2 000168329 594__ $$a2.5$$b2021 000168329 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000168329 700__ $$aPenela D 000168329 700__ $$0(orcid)0000-0001-9187-1773$$aJáuregui B 000168329 700__ $$aSoto-Iglesias D 000168329 773__ $$g44, 6 (2021), 1115-1125$$pPacing clin. electrophysiol.$$tPACE-PACING AND CLINICAL ELECTROPHYSIOLOGY$$x0147-8389 000168329 8564_ $$s1540148$$uhttps://zaguan.unizar.es/record/168329/files/texto_completo.pdf$$yPostprint 000168329 8564_ $$s815125$$uhttps://zaguan.unizar.es/record/168329/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000168329 909CO $$ooai:zaguan.unizar.es:168329$$particulos$$pdriver 000168329 951__ $$a2026-02-04-13:13:52 000168329 980__ $$aARTICLE